Cancer vaccines grant the advantages of having a very mild and manageable toxicity profile when compared with any other antitumoral treatment, even targeted HER-2 therapies, a very favourable posology, with no need for frequent administrations, and of providing a long-term and durable immune response specifically targeted against the tumor [136,137]. This evidence concerns the gene ERBB2 and neoplasm.